Gyre Therapeutics (GYRE) Receivables (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Receivables data on file, last reported at $26.8 million in Q1 2026.

• Receivables for Q1 2026 came in at $26.8 million, up 29.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.8 million (up 29.08% YoY), and the FY2025 annual result was $31.4 million, up 56.93% from the prior year.
• Receivables retreated to $26.8 million in Q1 2026 per GYRE's latest filing, from $31.4 million in the prior quarter.
• Over five years, Receivables peaked at $31.4 million in Q4 2025 and troughed at $564000.0 in Q1 2022.
• A 5-year average of $16.9 million and a median of $19.1 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables tumbled 43.94% in 2022, then jumped 786.52% in 2023.
• A 5-year view of Receivables shows it stood at $15.7 million in 2022, then grew by 1.43% to $16.0 million in 2023, then gained by 25.47% to $20.0 million in 2024, then jumped by 56.93% to $31.4 million in 2025, then slipped by 14.79% to $26.8 million in 2026.
• Business Quant data shows GYRE's Receivables at $26.8 million in Q1 2026, $31.4 million in Q4 2025, and $26.3 million in Q3 2025.